The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GnRHa Peptide Drugs Market Research Report 2024
Synopsis
Relin drugs refer to a large class of synthetic polypeptide drugs based on the structure of gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). Clinically, it is mainly used to treat symptoms such as low sexual function, anovulation, and delayed puberty, such as prostate cancer, uterine fibroids, breast cancer, endometriosis, and precocious puberty. At present, the main relin drugs in clinical use include: three main products of leuprorelin, goserelin and triptorelin.
Global GnRHa Peptide Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GnRHa Peptide Drugs market research.
Key manufacturers engaged in the GnRHa Peptide Drugs industry include Pfizer, AbbVie, AstraZeneca, Ferring, TerSera Therapeutics, Astellas Pharma, Takeda, LIVZON and Ipsen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GnRHa Peptide Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GnRHa Peptide Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GnRHa Peptide Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
AbbVie
AstraZeneca
Ferring
TerSera Therapeutics
Astellas Pharma
Takeda
LIVZON
Ipsen
Sanofi
Endo
Tocris Bioscience
Sigma-Aldrich
MedChem Express
Arbor Pharmaceuticals
Segment by Type
Prostap
Zoladex
Triptorelin
Histrelin
Nafarelin
Others
Segment by Application
Endometriosis
Uterine Fibroids
Artificial Assisted Reproduction
Prostate Cancer
Central Precocious Puberty
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GnRHa Peptide Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Relin drugs refer to a large class of synthetic polypeptide drugs based on the structure of gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). Clinically, it is mainly used to treat symptoms such as low sexual function, anovulation, and delayed puberty, such as prostate cancer, uterine fibroids, breast cancer, endometriosis, and precocious puberty. At present, the main relin drugs in clinical use include: three main products of leuprorelin, goserelin and triptorelin.
Global GnRHa Peptide Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GnRHa Peptide Drugs market research.
Key manufacturers engaged in the GnRHa Peptide Drugs industry include Pfizer, AbbVie, AstraZeneca, Ferring, TerSera Therapeutics, Astellas Pharma, Takeda, LIVZON and Ipsen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of GnRHa Peptide Drugs were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GnRHa Peptide Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GnRHa Peptide Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
AbbVie
AstraZeneca
Ferring
TerSera Therapeutics
Astellas Pharma
Takeda
LIVZON
Ipsen
Sanofi
Endo
Tocris Bioscience
Sigma-Aldrich
MedChem Express
Arbor Pharmaceuticals
Segment by Type
Prostap
Zoladex
Triptorelin
Histrelin
Nafarelin
Others
Segment by Application
Endometriosis
Uterine Fibroids
Artificial Assisted Reproduction
Prostate Cancer
Central Precocious Puberty
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The GnRHa Peptide Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 GnRHa Peptide Drugs Market Overview
1.1 Product Overview and Scope of GnRHa Peptide Drugs
1.2 GnRHa Peptide Drugs Segment by Type
1.2.1 Global GnRHa Peptide Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Prostap
1.2.3 Zoladex
1.2.4 Triptorelin
1.2.5 Histrelin
1.2.6 Nafarelin
1.2.7 Others
1.3 GnRHa Peptide Drugs Segment by Application
1.3.1 Global GnRHa Peptide Drugs Market Value by Application: (2023-2029)
1.3.2 Endometriosis
1.3.3 Uterine Fibroids
1.3.4 Artificial Assisted Reproduction
1.3.5 Prostate Cancer
1.3.6 Central Precocious Puberty
1.3.7 Others
1.4 Global GnRHa Peptide Drugs Market Size Estimates and Forecasts
1.4.1 Global GnRHa Peptide Drugs Revenue 2018-2029
1.4.2 Global GnRHa Peptide Drugs Sales 2018-2029
1.4.3 Global GnRHa Peptide Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GnRHa Peptide Drugs Market Competition by Manufacturers
2.1 Global GnRHa Peptide Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global GnRHa Peptide Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global GnRHa Peptide Drugs Average Price by Manufacturers (2018-2023)
2.4 Global GnRHa Peptide Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of GnRHa Peptide Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GnRHa Peptide Drugs, Product Type & Application
2.7 GnRHa Peptide Drugs Market Competitive Situation and Trends
2.7.1 GnRHa Peptide Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest GnRHa Peptide Drugs Players Market Share by Revenue
2.7.3 Global GnRHa Peptide Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GnRHa Peptide Drugs Retrospective Market Scenario by Region
3.1 Global GnRHa Peptide Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global GnRHa Peptide Drugs Global GnRHa Peptide Drugs Sales by Region: 2018-2029
3.2.1 Global GnRHa Peptide Drugs Sales by Region: 2018-2023
3.2.2 Global GnRHa Peptide Drugs Sales by Region: 2024-2029
3.3 Global GnRHa Peptide Drugs Global GnRHa Peptide Drugs Revenue by Region: 2018-2029
3.3.1 Global GnRHa Peptide Drugs Revenue by Region: 2018-2023
3.3.2 Global GnRHa Peptide Drugs Revenue by Region: 2024-2029
3.4 North America GnRHa Peptide Drugs Market Facts & Figures by Country
3.4.1 North America GnRHa Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America GnRHa Peptide Drugs Sales by Country (2018-2029)
3.4.3 North America GnRHa Peptide Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe GnRHa Peptide Drugs Market Facts & Figures by Country
3.5.1 Europe GnRHa Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe GnRHa Peptide Drugs Sales by Country (2018-2029)
3.5.3 Europe GnRHa Peptide Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GnRHa Peptide Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific GnRHa Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific GnRHa Peptide Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific GnRHa Peptide Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GnRHa Peptide Drugs Market Facts & Figures by Country
3.7.1 Latin America GnRHa Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America GnRHa Peptide Drugs Sales by Country (2018-2029)
3.7.3 Latin America GnRHa Peptide Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GnRHa Peptide Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa GnRHa Peptide Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa GnRHa Peptide Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa GnRHa Peptide Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GnRHa Peptide Drugs Sales by Type (2018-2029)
4.1.1 Global GnRHa Peptide Drugs Sales by Type (2018-2023)
4.1.2 Global GnRHa Peptide Drugs Sales by Type (2024-2029)
4.1.3 Global GnRHa Peptide Drugs Sales Market Share by Type (2018-2029)
4.2 Global GnRHa Peptide Drugs Revenue by Type (2018-2029)
4.2.1 Global GnRHa Peptide Drugs Revenue by Type (2018-2023)
4.2.2 Global GnRHa Peptide Drugs Revenue by Type (2024-2029)
4.2.3 Global GnRHa Peptide Drugs Revenue Market Share by Type (2018-2029)
4.3 Global GnRHa Peptide Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global GnRHa Peptide Drugs Sales by Application (2018-2029)
5.1.1 Global GnRHa Peptide Drugs Sales by Application (2018-2023)
5.1.2 Global GnRHa Peptide Drugs Sales by Application (2024-2029)
5.1.3 Global GnRHa Peptide Drugs Sales Market Share by Application (2018-2029)
5.2 Global GnRHa Peptide Drugs Revenue by Application (2018-2029)
5.2.1 Global GnRHa Peptide Drugs Revenue by Application (2018-2023)
5.2.2 Global GnRHa Peptide Drugs Revenue by Application (2024-2029)
5.2.3 Global GnRHa Peptide Drugs Revenue Market Share by Application (2018-2029)
5.3 Global GnRHa Peptide Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer GnRHa Peptide Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AbbVie
6.2.1 AbbVie Corporation Information
6.2.2 AbbVie Description and Business Overview
6.2.3 AbbVie GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie GnRHa Peptide Drugs Product Portfolio
6.2.5 AbbVie Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 AstraZeneca GnRHa Peptide Drugs Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Ferring
6.4.1 Ferring Corporation Information
6.4.2 Ferring Description and Business Overview
6.4.3 Ferring GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ferring GnRHa Peptide Drugs Product Portfolio
6.4.5 Ferring Recent Developments/Updates
6.5 TerSera Therapeutics
6.5.1 TerSera Therapeutics Corporation Information
6.5.2 TerSera Therapeutics Description and Business Overview
6.5.3 TerSera Therapeutics GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 TerSera Therapeutics GnRHa Peptide Drugs Product Portfolio
6.5.5 TerSera Therapeutics Recent Developments/Updates
6.6 Astellas Pharma
6.6.1 Astellas Pharma Corporation Information
6.6.2 Astellas Pharma Description and Business Overview
6.6.3 Astellas Pharma GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Astellas Pharma GnRHa Peptide Drugs Product Portfolio
6.6.5 Astellas Pharma Recent Developments/Updates
6.7 Takeda
6.6.1 Takeda Corporation Information
6.6.2 Takeda Description and Business Overview
6.6.3 Takeda GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Takeda GnRHa Peptide Drugs Product Portfolio
6.7.5 Takeda Recent Developments/Updates
6.8 LIVZON
6.8.1 LIVZON Corporation Information
6.8.2 LIVZON Description and Business Overview
6.8.3 LIVZON GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 LIVZON GnRHa Peptide Drugs Product Portfolio
6.8.5 LIVZON Recent Developments/Updates
6.9 Ipsen
6.9.1 Ipsen Corporation Information
6.9.2 Ipsen Description and Business Overview
6.9.3 Ipsen GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Ipsen GnRHa Peptide Drugs Product Portfolio
6.9.5 Ipsen Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sanofi GnRHa Peptide Drugs Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
6.11 Endo
6.11.1 Endo Corporation Information
6.11.2 Endo GnRHa Peptide Drugs Description and Business Overview
6.11.3 Endo GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Endo GnRHa Peptide Drugs Product Portfolio
6.11.5 Endo Recent Developments/Updates
6.12 Tocris Bioscience
6.12.1 Tocris Bioscience Corporation Information
6.12.2 Tocris Bioscience GnRHa Peptide Drugs Description and Business Overview
6.12.3 Tocris Bioscience GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Tocris Bioscience GnRHa Peptide Drugs Product Portfolio
6.12.5 Tocris Bioscience Recent Developments/Updates
6.13 Sigma-Aldrich
6.13.1 Sigma-Aldrich Corporation Information
6.13.2 Sigma-Aldrich GnRHa Peptide Drugs Description and Business Overview
6.13.3 Sigma-Aldrich GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Sigma-Aldrich GnRHa Peptide Drugs Product Portfolio
6.13.5 Sigma-Aldrich Recent Developments/Updates
6.14 MedChem Express
6.14.1 MedChem Express Corporation Information
6.14.2 MedChem Express GnRHa Peptide Drugs Description and Business Overview
6.14.3 MedChem Express GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.14.4 MedChem Express GnRHa Peptide Drugs Product Portfolio
6.14.5 MedChem Express Recent Developments/Updates
6.15 Arbor Pharmaceuticals
6.15.1 Arbor Pharmaceuticals Corporation Information
6.15.2 Arbor Pharmaceuticals GnRHa Peptide Drugs Description and Business Overview
6.15.3 Arbor Pharmaceuticals GnRHa Peptide Drugs Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Arbor Pharmaceuticals GnRHa Peptide Drugs Product Portfolio
6.15.5 Arbor Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GnRHa Peptide Drugs Industry Chain Analysis
7.2 GnRHa Peptide Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GnRHa Peptide Drugs Production Mode & Process
7.4 GnRHa Peptide Drugs Sales and Marketing
7.4.1 GnRHa Peptide Drugs Sales Channels
7.4.2 GnRHa Peptide Drugs Distributors
7.5 GnRHa Peptide Drugs Customers
8 GnRHa Peptide Drugs Market Dynamics
8.1 GnRHa Peptide Drugs Industry Trends
8.2 GnRHa Peptide Drugs Market Drivers
8.3 GnRHa Peptide Drugs Market Challenges
8.4 GnRHa Peptide Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
